Thomas R. Cox, Apr 2017
ROCK-ing pancreatic cancer to the core
Our new paper on short-term pulsed treatment, or ‘priming’ as a treatment strategy to boost chemotherapy has just been published in Science Translational Medicine.
STM Front Cover Vol 9 Issue 384 (Image: Timpson Laboratory, Garvan Institute)
The research, spearheaded by Dr. Paul Timpson and Dr. Marina Pajic here at the Garvan Institute of Medical Research in Sydney, has uncovered a promising new approach to treating pancreatic cancer. By targeting the tissue surrounding the tumour to make it ‘softer’, it leads to tumours being more responsive to chemotherapy.
Thomas R. Cox, Mar 2017
Pre-metastatic niches: organ-specific homes for metastases
Our new review on the importance of the pre-metastatic niche (PMN) in cancer has just been published in Nature Reviews Cancer. It summarises the natural progression of pre-metastatic niche formation and evolution, highlighting recent advances and future hurdles.
What is the pre-metastatic niche (PMN)?
Thomas R. Cox, Feb 2017
Our new paper on the pre-clinical testing of two novel potential anti-cancer drugs in breast cancer has just been published in Oncotarget.
Thomas R. Cox, Jan 2017
Our new protocol on in vitro shear rheology of cell-embedded hydrogels has just been published in bio-protocol
Bio-protocol (ISSN: 2331-8325) is a peer-viewed e-journal established in 2011 by a group of Stanford researchers. Their mission is to make life science research more efficient and reproducible by curating and hosting high quality, open access, life science protocols.
Thomas R. Cox, Oct 2016
Our new article as part of a special issue of the Journal of Bone Oncology focusing on The role of the microenvironment in bone metastasis is now out:
Thomas R. Cox, Jun 2016
Fibrosis and Cancer: Partners in Crime or Opposing Forces?
Our recent forum discussing the importance of cancer associated fibrosis in pancreatic cancer has just been published in Trends in Cancer
Targeting the Extracellular Matrix (ECM) in Pancreatic Ductal Adenocarcinoma (PDAC).
What is cancer associated fibrosis?
Thomas R. Cox, May 2016
In collaboration with the department of oncology and department of clinical and experimental medicine at Linköping University in Sweden, we have just published a new paper looking at the importance of lysyl oxidase (LOX) in rectal cancer patients.
Thomas R. Cox, Jan 2016
Over the last 2 decades there has been a rapidly increasing number of research papers published (many from our own lab) investigating the function and role of a secreted enzyme called Lysyl Oxidase (LOX). Each paper has added successive small pieces to the complex puzzle of what exactly LOX does in both normal development and human disease, none less so than cancer.
The last decade has seen an explosion in the number of papers reporting on Lysyl Oxidase (LOX)
Thomas R. Cox, Nov 2015
As part of our recent Nature paper (see previous post here) we sought to catalogue all of the different proteins secreted by breast cancer cells (the secretome) under conditions of hypoxia (low oxygen). Hypoxia is a common feature of most solid tumours and is very important in determining how cancer cells behave. Our hypothesis was that the breast cancer secretome changes under hypoxic conditions and that these changes were important in determining the how a patient’s tumour spreads around the body.
To create this catalogue, we performed Mass Spectrometry, a powerful analytical chemistry technique which allows us to both indentify and quantify proteins in a given sample. By creating a list of all the proteins present in the secretome of breast cancer cells, we were able to identify important proteins which may be responsible for determining how and where breast cancer spreads. In our paper we chose to focus specifically on one of these identified secreted proteins called Lysyl Oxidase (LOX).
Open Access – Open Data
Thomas R. Cox, Sep 2015
Linding Lab publishes back-to-back papers in Cell explaining how genetic cancer mutations systematically attack the networks controlling human cells
Today Professor Rune Linding at the Biotech Research & Innovation Centre (BRIC), University of Copenhagen (UCPH) along with collaborators at BRIC UCPH, Yale, University of Zurich (UZH), University of Rome and University of Tottori, have published back-to-back papers in Cell unravelling how disease mutations target and damage the protein signalling networks within human cells.
doi:10.1016/j.cell.2015.08.056 and doi:10.1016/j.cell.2015.08.057